### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-browser-links.json`
- `deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-browser.txt`
- `deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-targeted-check.txt`

The located artifacts do not state a reliable source-comparison count. No count is inferred.

**Existing source reconciliation:** Yes; 9 primary identifiers; selected mechanistic Methods/Results passage and caveat about overall nonsignificant SV2A result; correction notice flagged. Do not transfer separate psilocybin-dual-phase run; selected mechanistic check does not establish human mediation; 2025 mouse study has correction notice.

Matched primary identifiers in the preserved dated ledger: PMID 27210031, PMID 33852780, PMID 34228959, PMID 36322843, PMID 37651119, PMID 40175553, PMID 41224969, PMID 42138922, PMID 42457666. These are historical checks, not newly credited complete-paper examinations.

Shared template wording about an amyloid-specific Deep follow-up is not credited as a case-specific run for this topic. The actual raw case records above establish provider use.

No earlier adversarial approval has been verified for this edition at the supplement date. This provenance supplement has no separate approval and is not an independent or blinded adjudication. No score or confidence change is made by this reconciliation.